ID
45157
Descrição
Principal Investigator: Alan Shuldiner, MD, University of Maryland Baltimore, Baltimore, MD, USA MeSH: Pharmacogenomics,Clopidogrel,Platelets https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000391 CHD is the leading cause of death in the United States. One of the most common ways to prevent CHD is to take an anti-platelet agent, which lessens platelet aggregation. Two of the most common anti-platelet agents are aspirin and clopidogrel. However, up to 25% to 30% of people do not respond to these medications. Evidence indicates that treatment response may be related to genetics. The purpose of this study is to determine specific gene variants that predict response to aspirin and clopidogrel therapy. This study is part of a larger group of studies called the Pharmacogenomics Research Network (PGRN). Participants are from the Old Order Amish of Lancaster, Pennsylvania. They are well suited for genetic studies because they are a homogenous, closed, founder population. Participants received 300 mg of clopidogrel on the first day, then 75 mg of clopidogrel per day for the next 6 days. On the last day of clopidogrel treatment, participants took a single dose of 324 mg aspirin. Participants underwent platelet function tests before and after clopidogrel alone, and then again after taking clopidogrel plus aspirin. Using the gene variation profiles across the genome, researchers analyzed which variants correspond to treatment response.
Link
Palavras-chave
Versões (2)
- 2/9/22 2/9/22 - Niko Möller-Grell
- 12/10/22 12/10/22 - Adrian Schulz
Titular dos direitos
Alan Shuldiner, MD, University of Maryland Baltimore, Baltimore, MD, USA
Transferido a
12 de octubre de 2022
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
dbGaP phs000391 Pharmacogenomics of Anti-Platelet Intervention (PAPI) Study
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
- Subject ID and sample ID of participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
- Subject ID, age, sex, body mass index, systolic and diastolic blood pressure, waist circumference, fasting triglycerides, total cholesterol, LHD, HDL, baseline whole blood max aggregation of ADP, of arachidonic acid, and collagen 1, post plavix/pre aspirin whole blood max aggregation of ADP, of arachadonic acid, and collagen 1, baseline platelet rich plasma max aggregation of ADP, of collagen 2, of Epi, and arachadonic acid, post plavix/pre aspirin platelet rich plasma max aggregation of ADP, of Epi, and arachadonic acid, post plavix/post aspirin platelet rich plasma max aggregation of ADP, of collagen 2, of Epi, of arachadonic acid obtained from participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
- Subject ID and sample ID of participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
- Subject ID, age, sex, body mass index, systolic and diastolic blood pressure, waist circumference, fasting triglycerides, total cholesterol, LHD, HDL, baseline whole blood max aggregation of ADP, of arachidonic acid, and collagen 1, post plavix/pre aspirin whole blood max aggregation of ADP, of arachadonic acid, and collagen 1, baseline platelet rich plasma max aggregation of ADP, of collagen 2, of Epi, and arachadonic acid, post plavix/pre aspirin platelet rich plasma max aggregation of ADP, of Epi, and arachadonic acid, post plavix/post aspirin platelet rich plasma max aggregation of ADP, of collagen 2, of Epi, of arachadonic acid obtained from participants involved in the "Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)" project.
C0439092 (UMLS CUI [2,1])
C4082120 (UMLS CUI [2,2])
C0086839 (UMLS CUI [2,3])
C1321132 (UMLS CUI [2,1])
C1319171 (UMLS CUI [1,2])
C0392747 (UMLS CUI [1,3])
C93407 (UMLS CUI [1,4])
C1548265 (UMLS CUI [1,2])
C0006826 (UMLS CUI [1,2])
C0580476 (UMLS CUI [2,1])
C0151905 (UMLS CUI [3,1])
C1295607 (UMLS CUI [4,1])
C0586553 (UMLS CUI [5,1])
C0262926 (UMLS CUI [2,1])
C0017181 (UMLS CUI [2,2])
C0262926 (UMLS CUI [3,1])
C0019080 (UMLS CUI [3,2])
C0558681 (UMLS CUI [1,2])
C5545962 (UMLS CUI [1,3])
C0836924 (UMLS CUI [2,1])
C0205156 (UMLS CUI [1,2])
C4082120 (UMLS CUI [1,3])
C1689910 (UMLS CUI [2,1])
Sem comentários